Vilacto Bio Inc. (fka VIBI)

[stervc]

VIBI Key Intel to Consider...

This is some old info from VIBI back when it was trading in the .70 per share area of which some of it could still apply (really focus on what's in bold):

https://microcapdaily.com/inside-scoop-on-vilacto-bio-inc-otcmkts-vibi/122822/
Inside Scoop on Vilacto Bio Inc (OTCMKTS: VIBI)
BY DANIEL MCCARTHY ON DECEMBER 27, 2018

Vilacto Bio Inc (OTCMKTS: VIBI) is an exciting stock that popped to $0.70 a share in October but has been dropping steadily since than recently hitting single digits.

Vilacto Bio Inc is a biotech company that has developed the now fully patented Lactoactive® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. The Company aims to further develop the Lactoactive® molecule for the purpose of increasing the quality of retail and medical skin cream products as well as licensing Lactoactive® molecule for the pharmaceutical industry.

The Company recently announced it has revealed the initial five areas of development for its new LACTOACTIVE iTHER® compound. These include a bio-injection that could be useful in preventing metastasis of malignant tumor cells in cancer treatment due to the hydrocolloid potent (HA). An inhaler spray to prevent recurrent upper respiratory tract infections (based on a 2016 study. A vaccine injection for nanoparticle antibody source for a vaccine producer or a new variant of gelatin capsules for patients with arthritis and other joint inflammation with fewer side effects – especially hypertension if people with diabetes – than Glucosamine.

LACTOACTIVE iTHER® is a new LACTOACTIVE variant that combines potent immune-system enhancement with a proven nanoparticle drug delivery system. These development programs are part of Vilacto Bio’s LACTOACTIVE iTHER® plan to form strategic partnerships with other biotech firms and become the “go-to” partner for enhancing new immunotherapy and vaccine solutions with its refined-colostrum compound “weaponized” as a nanomedicine.

VIBI CEO Gert Anderson stated “Our own research suggests, and we firmly believe, that LACTOACTIVE iTHER® can contribute significantly to emerging therapies for treating a number of diseases, including cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia and others.”

Earlier this year Vilacto Bio completed a two-month upgrade to the Denmark production facility, which is owned by Pharma GP, that produces its patented LACTOACTIVE nanoparticle compound. This upgrade will enable the company to manufacture even smaller LACTOACTIVE particles and enable Vilacto Bio to start production of its new LACTOACTIVE iTHER®.

In October VIBI announced it has launched its new skincare product, Carmen Electra by Vilact, based on the company’s LACTOACTIVE® compound. LACTOACTIVE® is the first variant of a patented particle the company has used to produce a range of popular skincare products. Customers have given Carmen Electra by Vilact rave reviews, and the new product won the “Buyers’ Choice” award at a ECRM event held in Las Vegas in June.

In addition to using the LACTOACTIVE® compound in its skin creams – now spun off as a separate business unit – Vilacto Bio is moving into biotech with its new LACTOACTIVE iTHER® compound. In the long run, Vilacto Bio expects LACTOACTIVE iTHER® to help develop further and even more powerful skincare solutions, along with therapeutic treatments for a range of medical conditions.

On November 30 VIBI announced it has secured the patent applications for LACTOACTIVE® covering rights in the US, Canada Europe and Hong Kong. The transaction was finalized this November. Ownership of the patent applications, which Vilacto Bio had been licensing the US rights from a Danish company, is expected to give the company greater scope to continue developing the LACTOACTIVE® compound, and bolster its international IP ownership position.

The patent applications also cover the company’s new compound, LACTOACTIVE iTHER®, a LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases. LACTOACTIVE iTHER® is expected to generate new revenue streams in addition to the company’s LACTOACTIVE®-based therapeutic skincare range..”

The main active component of LACTOACTIVE® and LACTOACTIVE iTHER® is colostrum, a natural substance that Vilacto Bio has refined and processed into a potent nanoparticle concentrate. In NPDDS form, the compound can be applied in deeper layers of the skin and, when injected, can penetrate cell walls to act directly on cytoplasm. The product is currently in the development stage and has not been approved for use by the FDA or any foreign agency.

v/r
Sterling